← Back to Screener
Pasithea Therapeutics Corp. Warrants (KTTAW)
Price$0.01
Favorite Metrics
Price vs S&P 500 (4W)-53.53%
All Metrics
Price vs S&P 500 (YTD)-51.16%
10-Day Avg Trading Volume0.02M
3-Month Avg Trading Volume0.04M
52-Week High$0.12
13-Week Price Return-38.02%
3-Month Return Std Dev686.03%
Year-to-Date Return-46.81%
5-Day Price Return-57.14%
Month-to-Date Return-33.63%
Price vs S&P 500 (13W)-39.15%
Beta1.38x
52-Week Low$0.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KTTAWPasithea Therapeutics Corp. Warrants | — | — | — | — | $0.01 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Pasithea Therapeutics is a biotechnology company developing treatments for central nervous system disorders, RASopathies, and select cancers. Its pipeline targets neurofibromatosis type 1, amyotrophic lateral sclerosis, multiple sclerosis, and schizophrenia, with lead candidates including PAS-004 (a MEK1/2 inhibitor), PAS-003 (a monoclonal antibody), and PAS-001.